Risk factors for major bleeding and for minor bleeding after percutaneous coronary intervention in 634 consecutive patients with acute coronary syndromes

American Journal of Therapeutics

Volumn 17, Issue 4, 2010, Pages

  Pierre Louis, Bredy ^a   Aronow, Wilbert S ^a   Yoon, Joo H ^a   Ahn, Chul ^b   Kalapatapu, Kumar ^a   Pucillo, Anthony L ^a   Monsen, Craig E ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

acute coronary syndromes; bleeding; glomerular filtration rate; percutaneous coronary intervention; troponin I

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; TROPONIN I; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CORONARY ARTERY DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HEMATOCRIT; HUMAN; LENGTH OF STAY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROPERITONEAL HEMATOMA; RISK FACTOR; STROKE; SYSTOLIC BLOOD PRESSURE; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; HEMORRHAGE; METABOLISM; MIDDLE AGED; MORTALITY; SEVERITY OF ILLNESS INDEX; TRANSLUMINAL CORONARY ANGIOPLASTY; VERY ELDERLY;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BLOOD PRESSURE; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HOSPITAL MORTALITY; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TROPONIN I; ANGIOPLASTY, BALLOON, CORONARY;

EID: 77954982697     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e318197ea8f     Document Type: Article

References (7)

1. Kinnaird TD, Stabile E, Mintz GS, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol. 2003;92:930-935.
2. Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY trial. J Am Coll Cardiol. 2007;49:1362-1368.
3. Lincoff AM, Bittl JA, Kleiman NS, et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 Trial). Am J Cardiol. 2004;93:1092-1096.
4. Lincoff AM, Kleiman NS, Kereiakes DJ, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA. 2004;292:696-703.
5. Nikolsky E, Mehran R, Dangas G, et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J. 2007;28:1936-1945.
6. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:461-470.
7. National Kidney Foundation. Kidney Disease Outcome Quality initiative (K/DOQI) clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(Suppl 1):S1-S266.